Jay R. Venkatesan

2023

In 2023, Jay R. Venkatesan earned a total compensation of $2.4M as former Chief Executive Officer, President, and Chairman of the Angion Board at Elicio Therapeutics, a 60% increase compared to previous year.

Compensation breakdown

Bonus$608,000
Option Awards$22,427
Salary$243,944
Other$1,554,904
Total$2,429,275

Venkatesan received $1.6M in other compensation, accounting for 64% of the total pay in 2023.

Venkatesan also received $608K in bonus, $22.4K in option awards and $243.9K in salary.

Rankings

In 2023, Jay R. Venkatesan's compensation ranked 408th out of 2,918 executives tracked by ExecPay. In other words, Venkatesan earned more than 86.0% of executives.

ClassificationRankingPercentile
All
408
out of 2,918
86th
Division
Manufacturing
233
out of 1,608
86th
Major group
Chemicals And Allied Products
164
out of 901
82nd
Industry group
Drugs
161
out of 864
81st
Industry
Pharmaceutical Preparations
100
out of 622
84th
Source: SEC filing on September 27, 2024.

Venkatesan's colleagues

We found four more compensation records of executives who worked with Jay R. Venkatesan at Elicio Therapeutics in 2023.

2023

Jennifer Rhodes

Elicio Therapeutics

General Counsel

2023

Brian Piekos

Elicio Therapeutics

Chief Financial Officer

2023

Robert Connelly

Elicio Therapeutics

Chief Executive Officer

2023

Christopher Haqq

Elicio Therapeutics

Chief Medical Officer

News

You may also like